110 results
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
1 Apr 24
Departure of Directors or Certain Officers
7:06am
, and possible safety and efficacy concerns. For a discussion of other risks and uncertainties, and other important factors, any of which could cause
10-K
2023 FY
EX-10.12
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
the meaning set out in Section 16.2. 1.20 “Autolus IP” means (a) [***] Licensed IP, (b) [***] Licensed IP, (c) Safety Switch Licensed IP, (d) Activity … “Autolus Patents” means (a) [***] Licensed Patents, (b) [***] Licensed Patents, (c) Safety Switch Licensed Patents, (d) Activity Enhancement Licensed
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
regulatory approval for and launch a product commercially.
Table of contents
Adverse side effects or other safety risks associated with our product … trials of any of our product candidates fail to demonstrate safety and efficacy to the satisfaction of the Food and Drug Administration (“FDA
8-K/A
EX-99.1
AUTL
Autolus Therapeutics plc
15 Mar 24
Results of Operations and Financial Condition
4:21pm
activity with combined with an excellent safety profile across all of these categories of risk in the patients treated in FELIX study. What we also … -cel in the adult ALL setting, which gives us a lot of safety data. It gives us obviously the regulatory packages, which are absolutely relevant
8-K
EX-99.2
AUTL
Autolus Therapeutics plc
14 Mar 24
Results of Operations and Financial Condition
12:32pm
clinical development, efficacy, safety and therapeutic potential of the Company's product candidates, including progress, expectations as to the reporting … to enroll patients in clinical trials; and possible safety and efficacy concerns. For a discussion of other risks and uncertainties, and other important
8-K
EX-99.1
exocnrkp
14 Mar 24
Results of Operations and Financial Condition
12:32pm
8-K
EX-99.1
hmfc kg0qu7
13 Feb 24
Regulation FD Disclosure
4:06pm
8-K
lxfdvxtr
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
8-K
EX-99.1
pxx 1w1k5
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
8-K
EX-99.1
1m1 7lt7vphm68m7hj
26 Jan 24
Regulation FD Disclosure
1:02pm
8-K
EX-99.1
vqz7rektb 52saxzp
10 Jan 24
Departure of Directors or Certain Officers
3:12pm
8-K
EX-99.1
olq34h m6amu
22 Dec 23
Departure of Directors or Certain Officers
8:24am
8-K
EX-99.2
gq9bpqq1tg68t6dalm7
11 Dec 23
Regulation FD Disclosure
8:31am
8-K
EX-99.1
gdk3j6busvf
11 Dec 23
Regulation FD Disclosure
8:31am
8-K
EX-99.1
pc1if
27 Nov 23
Regulation FD Disclosure
7:07am
10-Q
EX-10.1
3xh i33vk89j6fmct
9 Nov 23
Quarterly report
4:18pm
10-Q
5hh70usawry2 o1w
9 Nov 23
Quarterly report
4:18pm
6-K
EX-99.3
dkk890q636wgp i6
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm
6-K
EX-99.2
y6tbffi
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm
6-K
EX-99.1
x798 22x2
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm